



(12) Translation of
European patent specification

(11) NO/EP 3149045 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 45/06 (2006.01)

C07K 16/18 (2006.01)

A61K 35/00 (2006.01)

C07K 16/28 (2006.01)

A61P 31/12 (2006.01)

C12N 9/24 (2006.01)

A61P 35/02 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2023.03.13
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.01.18
(86)	European Application Nr.	15799981.4
(86)	European Filing Date	2015.05.27
(87)	The European Application's Publication Date	2017.04.05
(30)	Priority	2014.05.27, US, 201462003104 P 2014.05.27, US, 201462003136 P 2014.05.28, US, 201462003908 P 2014.07.02, US, 201462020199 P 2015.01.30, US, 201562110338 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Academia Sinica, 128, Academia Road, Section 2 Nankang, Taipei 11529, Taiwan
(72)	Inventor	WONG, Chi-Huey, P.O. Box 8154, Rancho Santa Fe, California 92067, USA WU, Chung-Yi, No. 78-1 Dongshi Street Xi-Zhi District, New Taipei City 221, Kina MA, Che, c/o Academia Sinica 128 Academia Road Section 2 Nankang, Taipei 11529, Kina
(74)	Agent or Attorney	Nordic Patent Service A/S, Bredgade 30, 1260 KØBENHAVN K, Danmark

(54)	Title	COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY
(56)	References Cited:	WO-A1-2013/011347, US-A1- 2014 086 916, US-A1- 2011 263 828, WO-A1-2013/120066 CARTER, P.: 'Potent antibody therapeutics by design' NATURE REVIEWS IMMUNOLOGY vol. 6, 07 April 2006, pages 343 - 357, XP007901440 BECK, A.: 'Biosimilar, biobetter and next generation therapeutic antibodies' MABS vol. 3, 01 March 2011, pages 107 - 110, XP055189402 SMYTH ET AL.: 'CD 4+ CD 25+ T Regulatory Cells Suppress NK Cell -Mediated Immunotherapy of Cancer' THE JOURNAL OF IMMUNOLOGY vol. 176, 2006, pages 1582 - 1587, XP002452474 WEI HUANG ET AL: "Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 134, no. 29, 25 July 2012 (2012-07-25), pages 12308-12318, XP055035929, ISSN: 0002-7863, DOI: 10.1021/ja3051266

LIU ET AL.: 'Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor- bearing host' BLOOD vol. 109, no. 10, 15 May 2007, pages 4336 - 4342, XP055238984
CHIN-WEI LIN ET AL: "A common glycan structure on immunoglobulin G for enhancement of effector functions", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 112, no. 34, 7 August 2015 (2015-08-07), pages 10611-10616, XP055292294, US ISSN: 0027-8424, DOI: 10.1073/pnas.1513456112

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Sammensetning omfattende anti-CD20-glykoantistoffer, hvori anti-CD20-glykoantistoffene er en homogen populasjon av Rituximab omfattende et enkelt, ensartet N-glykan på Fc-regionen og hvori N-glykanen er fri for kjernefukose og har strukturen til Sia₂(α2-
5 6)Gal₂GlcNAc₂Man₃GlcNAc₂, for anvendelse ved behandling av kreft hos en pasient som er resistent eller refraktær mot behandling med Rituximab.